| 効果 | 減少 |
| 試験方法 | 二重盲検法 |
| 試験期間 | 6+ ヶ月 |
| 被験者数 | 261 |
| 性別 | 男女 |
| 年齢 | 65+ |
| 体型 | 平均, Underweight |
この研究の注釈：
Supplementation of Alpha-GPC at 400mg thrice daily (1,200mg daily) for 180 days in persons with mild to moderate Alzheimer’s disease was able to improve symptoms as assessed by a multitude of rating scales including ADAS, MMSE, CDI, and GDS.